Abstract
This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV - zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy - a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present, there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068 - the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor.
Keywords: Antimicrobial resistance, cARV, fusion inhibitors, HAART, human immunodeficiency virus, inhibitors, nucleoside reverse transcriptase, protease inhibitors, sexually transmitted diseases.
Mini-Reviews in Medicinal Chemistry
Title:Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV
Volume: 15 Issue: 2
Author(s): Anna Majewska, Beata Mlynarczyk-Bonikowska, Magdalena Malejczyk, Grazyna Mlynarczyk and Slawomir Majewski
Affiliation:
Keywords: Antimicrobial resistance, cARV, fusion inhibitors, HAART, human immunodeficiency virus, inhibitors, nucleoside reverse transcriptase, protease inhibitors, sexually transmitted diseases.
Abstract: This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV - zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy - a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present, there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068 - the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor.
Export Options
About this article
Cite this article as:
Majewska Anna, Mlynarczyk-Bonikowska Beata, Malejczyk Magdalena, Mlynarczyk Grazyna and Majewski Slawomir, Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV, Mini-Reviews in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/138955751502150305154459
DOI https://dx.doi.org/10.2174/138955751502150305154459 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Editorial: The Importance of Case Reports and Case Series in Helping Diagnose Rare Diseases
Current Respiratory Medicine Reviews Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Structure Based Drug Design for HIV Protease: From Molecular Modeling to Cheminformatics
Current Topics in Medicinal Chemistry Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Current Protein & Peptide Science From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals